- Home
- CMMB vs STRR Comparison
CMMB vs STRR Comparison
Compare CMMB & STRR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- STRR
- Stock Information
- Founded
- CMMB 2004
- STRR 1985
- Country
- CMMB Israel
- STRR United States
- Employees
- CMMB N/A
- STRR N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- STRR Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CMMB Health Care
- STRR Health Care
- Exchange
- CMMB Nasdaq
- STRR Nasdaq
- Market Cap
- CMMB 15.8M
- STRR 13.1M
- IPO Year
- CMMB N/A
- STRR N/A
- Fundamental
- Price
- CMMB $1.51
- STRR $4.16
- Analyst Decision
- CMMB Strong Buy
- STRR
- Analyst Count
- CMMB 3
- STRR 0
- Target Price
- CMMB $5.67
- STRR N/A
- AVG Volume (30 Days)
- CMMB 229.7K
- STRR 9.8K
- Earning Date
- CMMB 11-07-2024
- STRR 11-06-2024
- Dividend Yield
- CMMB N/A
- STRR N/A
- EPS Growth
- CMMB N/A
- STRR N/A
- EPS
- CMMB N/A
- STRR N/A
- Revenue
- CMMB N/A
- STRR $47,147,000.00
- Revenue This Year
- CMMB N/A
- STRR $19.97
- Revenue Next Year
- CMMB N/A
- STRR $41.50
- P/E Ratio
- CMMB N/A
- STRR N/A
- Revenue Growth
- CMMB N/A
- STRR N/A
- 52 Week Low
- CMMB $0.42
- STRR $3.43
- 52 Week High
- CMMB $2.55
- STRR $6.55
- Technical
- Relative Strength Index (RSI)
- CMMB 43.28
- STRR 49.54
- Support Level
- CMMB $1.29
- STRR $4.06
- Resistance Level
- CMMB $1.78
- STRR $4.55
- Average True Range (ATR)
- CMMB 0.15
- STRR 0.26
- MACD
- CMMB -0.05
- STRR 0.01
- Stochastic Oscillator
- CMMB 36.73
- STRR 41.79
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About STRR Star Equity Holdings Inc.
Star Equity Holdings Inc is a multi-industry diversified holding company with two segments: The construction segment manufactures modular housing units for commercial and residential applications. It operates in two businesses: modular building manufacturing and structural wall panel and wood foundation manufacturing, including building supply retail operations, and The investments segment holds corporate-owned real estate, which currently includes two manufacturing facilities in Maine that it leases back to KBS and manufacturing facility. The company derives maximum revenue from Construction Segment.